Trial ID	Intervention(s) and comparator(s)	Randomised /safety (N)	Hypoglycaemic episodes, severe nocturnal (n/N (%))	Hypoglycaemic episodes, SAE (n/N (%))	Hypoglycaemic episodes, nocturnal (n/N (%))	Hyperglycaemic/ketoacidotic episodes (n/N (%))
Altuntas 2003	I: insulin lispro	20	—	—	—	—
	C: RHI	20	—	—	—	—
Bastyr 2000	I: insulin lispro	186	—	—	—	3/186 (2)
	C: RHI	189	—	—	—	3/189 (2)
Dailey 2004	I: insulin glulisine	‐/435	—	—	89/416a,b	—
	C: RHI	‐/441	—	—	103/420a,b	—
	All	878c/876	—	—	192/836a,b	—
Hermann 2013	I: insulin aspart	18	—	—	—	—
	C: RHI	11	—	—	—	—
NCT01650129	I: biphasic insulin aspart 50	58	—	—	—	—
	C: biphasic human insulin 50/50	26	—	—	—	—
Pfützner 2013	I1: insulin aspart	4	—	—	—	—
	I2: insulin glulisine	4	—	—	—	—
	C: RHI	4	—	—	—	—
Rayman 2007	I: insulin glulisine	448	3/‐d (1)	‐	95/‐d (21)	‐
	C: RHI	444c/442	5/‐d (1)	‐	100/‐d (23)	‐
Ross 2001	I: insulin lispro	70	—	—	—	—
	C: RHI	78	—	—	—	—
Z012 1997	I: insulin lispro	72	—	—	—	0/72 (0)
	C: RHI	73	—	—	—	1/73 (1)
Z014 1997	I: insulin lispro	73	—	—	—	1/73 (1)
	C: RHI	77	—	—	—	1/77 (1)
aBased on author's response in IQWIG 2005 bOnly for the period month 4 to study end cTwo participants not exposed to treatment dAccording to IQWIG 2005, the total number of participants should be 448 and 442 (deducted from percentage numbers presented in the original study report), but in the same table it is also reported that there are 21 and 8 missing values. —: denotes not reported C: comparator; I: intervention; RHI: regular human insulin; SAE: serious adverse events